[go: up one dir, main page]

FR22C1001I2 - Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente - Google Patents

Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente

Info

Publication number
FR22C1001I2
FR22C1001I2 FR22C1001C FR22C1001C FR22C1001I2 FR 22C1001 I2 FR22C1001 I2 FR 22C1001I2 FR 22C1001 C FR22C1001 C FR 22C1001C FR 22C1001 C FR22C1001 C FR 22C1001C FR 22C1001 I2 FR22C1001 I2 FR 22C1001I2
Authority
FR
France
Prior art keywords
protein
conjugate vaccine
polysaccharide conjugate
meningococcal disease
polyvalent meningococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1001C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1001(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of FR22C1001I1 publication Critical patent/FR22C1001I1/fr
Application granted granted Critical
Publication of FR22C1001I2 publication Critical patent/FR22C1001I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR22C1001C 2001-01-23 2022-01-06 Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente Active FR22C1001I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
EP10183565.0A EP2332581B1 (fr) 2001-01-23 2002-01-22 Vaccin de meningocoque tri- ou tetravalent préparé avec un conjugué de polysaccharide et de CRM197
PCT/US2002/001963 WO2002058737A2 (fr) 2001-01-23 2002-01-22 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine
EP02707551A EP1355673B1 (fr) 2001-01-23 2002-01-22 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine

Publications (2)

Publication Number Publication Date
FR22C1001I1 FR22C1001I1 (fr) 2022-02-18
FR22C1001I2 true FR22C1001I2 (fr) 2025-02-07

Family

ID=23001755

Family Applications (3)

Application Number Title Priority Date Filing Date
FR12C0072C Active FR12C0072I2 (fr) 2001-01-23 2012-11-29 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine
FR15C0094C Active FR15C0094I2 (fr) 2001-01-23 2015-12-21 Vaccin de meningocoque tri- ou tetravalent prepare avec un conjugue de polysaccharide et de crm197
FR22C1001C Active FR22C1001I2 (fr) 2001-01-23 2022-01-06 Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FR12C0072C Active FR12C0072I2 (fr) 2001-01-23 2012-11-29 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine
FR15C0094C Active FR15C0094I2 (fr) 2001-01-23 2015-12-21 Vaccin de meningocoque tri- ou tetravalent prepare avec un conjugue de polysaccharide et de crm197

Country Status (38)

Country Link
US (9) US8722062B2 (fr)
EP (3) EP2957300B1 (fr)
JP (6) JP2005504718A (fr)
KR (2) KR100947757B1 (fr)
CN (1) CN100556459C (fr)
AP (1) AP1897A (fr)
AU (2) AU2007216743A1 (fr)
BE (3) BE2012C050I2 (fr)
BR (1) BRPI0206672B8 (fr)
CA (1) CA2435681C (fr)
CR (1) CR7035A (fr)
CY (2) CY1113072T1 (fr)
DK (2) DK2332581T3 (fr)
EA (1) EA006947B1 (fr)
EC (1) ECSP034701A (fr)
ES (3) ES2388848T3 (fr)
FR (3) FR12C0072I2 (fr)
GE (1) GEP20053691B (fr)
HR (1) HRP20030598B1 (fr)
HU (2) HU230490B1 (fr)
IL (3) IL157060A0 (fr)
IS (1) IS6881A (fr)
LT (1) LT5177B (fr)
LU (1) LU92108I2 (fr)
LV (1) LV13128B (fr)
MX (2) MXPA03006561A (fr)
NO (1) NO20033816L (fr)
NZ (2) NZ622900A (fr)
OA (1) OA12590A (fr)
PL (1) PL226184B1 (fr)
PT (2) PT2332581E (fr)
RO (1) RO122761B1 (fr)
SI (1) SI21352A (fr)
TN (1) TNSN03041A1 (fr)
UA (1) UA92579C2 (fr)
WO (1) WO2002058737A2 (fr)
YU (1) YU66103A (fr)
ZA (1) ZA200306176B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100947757B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2004033623A2 (fr) * 2002-05-16 2004-04-22 Aventis Pasteur, Inc. Fermentation de polysaccharides meningococciques exempte de constituant animal et developpement de banque de semences
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CA2506090A1 (fr) * 2002-11-14 2004-05-27 Carmen Rosa Soto Rodriguez Procede d'obtention de vaccins conjugues et de compositions vaccinales qui les contiennent.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2383175T3 (es) * 2003-01-30 2012-06-18 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
KR20060035581A (ko) * 2003-03-07 2006-04-26 와이어쓰 홀딩스 코포레이션 병원내 감염에 대한 면역화에 유용한다당류-스타필로코커스 표면 부착소 운반체 단백질 접합체
CN1819843A (zh) * 2003-05-07 2006-08-16 安万特巴斯德公司 增强脑膜炎球菌疫苗接种免疫原性的方法
US9107831B2 (en) * 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
CA2530364C (fr) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccins contre neisseria meningitidis du groupe y et combinaisons meningococciques desdits vaccins
US20050019337A1 (en) * 2003-06-23 2005-01-27 Ryall Robert P. Immunization method against Neisseria meningitidis serogroups A and C
PL1670506T3 (pl) 2003-10-02 2013-04-30 Novartis Ag Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005105140A2 (fr) * 2004-04-30 2005-11-10 Chiron Srl Integration d'une vaccination conjuguee antimeningococcique
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1784214A4 (fr) * 2004-08-30 2009-09-23 Sanofi Pasteur Inc Conjugués polysaccharide/protéine dérivatisés de méningocoque multivalents et vaccin
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
EP2345422A1 (fr) * 2004-09-21 2011-07-20 Sanofi Pasteur, Inc. Conjugués de polysaccharides-protéines dérivatisés méningococciques multivalents et vaccin
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP1871411A4 (fr) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
BRPI0612655B1 (pt) 2005-06-27 2021-06-15 Pfizer Ireland Pharmaceuticals Composição imunogênica
AU2006286228A1 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
KR20130135399A (ko) * 2006-03-17 2013-12-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
WO2007116409A2 (fr) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Vaccins améliorés comprenant des supports peptidiques multimères dérivés de la hsp60
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2008259423A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (fr) 2008-12-17 2010-06-24 Novartis Ag Vaccins méningococciques comprenant un récepteur de l'hémoglobine
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
WO2012020326A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantés contre le méningocoque de sérogroupe b
ES2994878T3 (en) 2010-08-23 2025-02-03 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2744471T3 (es) * 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
CA2828844C (fr) 2011-03-02 2020-07-14 Novartis Ag Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
EP2822584A1 (fr) 2012-03-08 2015-01-14 Novartis AG Vaccins combinés comprenant des agonistes du tlr4
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
SG11201500566XA (en) * 2012-08-16 2015-04-29 Pfizer Glycoconjugation processes and compositions
CA2882619A1 (fr) 2012-09-06 2014-03-13 Novartis Ag Vaccins combinatoires avec meningococcus de serogroupe b et d/t/p
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
BR112015014250A2 (pt) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa método para imunizar um bebê, vacina de combinação e, kit
EP2964665B1 (fr) 2013-03-08 2018-08-01 Pfizer Inc Polypeptides immunogènes de fusion
BR112015024014A2 (pt) * 2013-03-18 2017-07-18 Glaxosmithkline Biologicals Sa vacina conjugada
MX2016000393A (es) 2013-07-11 2016-10-26 Novartis Ag Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
CA2923129C (fr) 2013-09-08 2020-06-09 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procedes associes
EP3148577B1 (fr) 2014-05-24 2021-01-20 Biological E Limited Nouveau vaccin conjugué méningococcique semi-synthétique
WO2016132294A1 (fr) 2015-02-19 2016-08-25 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
US20180064830A1 (en) 2015-02-20 2018-03-08 Bayer Healthcare Llc Contrast imaging agent with dissolved gas-evolving fluid
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
AU2016383022B2 (en) 2015-12-30 2021-04-01 Ascendis Pharma A/S Auto injector with cartridge retention system
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
EP4309670A3 (fr) * 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Vaccin contre neisseria meningitidis
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2019198096A1 (fr) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Composition de vaccin méningococcique tétravalente et son procédé de préparation
EP3849637B1 (fr) 2018-09-12 2026-02-18 Bayer HealthCare LLC Système de conduite d'une procédure d'injection de fluide
EP3632465A1 (fr) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Immunisation combinée contre la méningite à méningocoques et le papillomavirus humain
WO2020168146A1 (fr) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Vaccin à base de snodgrassella alvi commensale d'abeilles contre neisseriaceae pathogènes
WO2021059181A1 (fr) 2019-09-27 2021-04-01 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
AU2020406676A1 (en) 2019-12-17 2022-06-23 9286-3620 Québec Inc. Oral delivery systems based on in situ forming protein/polysaccharide coacervates
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
KR20250031146A (ko) 2022-04-11 2025-03-06 사노피 파스퇴르 인크 소듐 시아노보로하이드라이드를 이용한 단백질-당류 접합
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
AU2024320804A1 (en) 2023-08-09 2026-01-29 Bayer Healthcare Llc Noble gas delivery device, cartridge, and triggering system for lung functional and structural imaging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
EP0109350B1 (fr) 1982-11-10 1991-10-16 Mitsubishi Jukogyo Kabushiki Kaisha Alliage nickel-chrome
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
DE3660966D1 (en) 1985-04-17 1988-11-24 Akzo Nv Method of applying a road marking composition
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) * 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
ES2070312T5 (es) 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2101648C (fr) 1991-03-12 2003-09-09 Rachel Schneerson Conjugues polysaccharide-proteine
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
HU9400426D0 (en) 1991-08-16 1994-05-30 Merck & Co Inc Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5422427A (en) * 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
UA40596C2 (uk) * 1992-05-23 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини та спосіб її одержання
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
WO1994005325A1 (fr) * 1992-08-31 1994-03-17 North American Vaccine, Inc. Vaccins contre la neisseria meningitidis du groupe c
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
HUP9802199A3 (en) 1995-06-07 1999-07-28 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ATE433329T1 (de) 1995-06-23 2009-06-15 Glaxosmithkline Biolog Sa Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
EP0959905B1 (fr) * 1997-01-21 2009-12-09 Sanofi Pasteur Conjugues de polysaccharide et de peptide
US6891037B1 (en) 1997-01-24 2005-05-10 Schweiz. Serum- & Impfinstitut Bern Method for the isolation of polysaccharides
US6403306B1 (en) 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
EP0977588B1 (fr) 1997-04-24 2004-10-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine Couplage de proteines non modifiees a des polysaccharides derives d'haloacyle ou de dihaloacyle pour la preparation de vaccins renfermant des proteines-polysaccharides
EP1849860B1 (fr) 1997-05-28 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Procédé de préparation d'un facteur immunogene de Corynebacterium diphtheriae en utilisant un milieu de culture avec extrait de levure en tant que source d'acides aminés et dépourvu de complexes protéiques d'origine animale
JP2002506448A (ja) * 1997-06-24 2002-02-26 カイロン コーポレイション 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
HUP0100623A3 (en) 1997-12-23 2003-11-28 Baxter Healthcare S A Wallisel Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
NZ513259A (en) 1999-02-01 2004-05-28 Eisai Co Ltd Immunological adjuvant compound containing a cardiolipin derivative
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
ES2563650T3 (es) 1999-05-19 2016-03-15 Glaxosmithkline Biologicals Sa Composiciones de combinaciones de Neisseria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4948731B2 (ja) 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 凍結乾燥の際に生物学的分子を安定化するための組成物および方法
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
CN1449293B (zh) 2000-06-29 2012-08-22 史密丝克莱恩比彻姆生物有限公司 多价疫苗组合物
KR100947757B1 (ko) * 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
US20030068336A1 (en) 2003-04-10
BR0206672A (pt) 2005-05-10
US20130216571A1 (en) 2013-08-22
BE2015C077I2 (fr) 2021-02-04
US20160000928A1 (en) 2016-01-07
AP2003002829A0 (en) 2003-09-30
YU66103A (sh) 2006-05-25
US20130224241A1 (en) 2013-08-29
PL373710A1 (en) 2005-09-05
JP2014043474A (ja) 2014-03-13
FR12C0072I2 (fr) 2013-11-01
EP1355673B1 (fr) 2012-05-30
JP2005504718A (ja) 2005-02-17
SI21352A (sl) 2004-06-30
JP5795721B2 (ja) 2015-10-14
EP1355673A2 (fr) 2003-10-29
BE2022C502I2 (fr) 2023-04-12
IL157060A0 (en) 2004-02-08
EP2957300A2 (fr) 2015-12-23
IL157060A (en) 2013-04-30
JP2014065745A (ja) 2014-04-17
CY2012030I1 (el) 2015-08-05
ECSP034701A (es) 2003-10-28
ES2388848T3 (es) 2012-10-19
HUP0302999A3 (en) 2011-05-30
BE2012C050I2 (fr) 2021-03-23
AP1897A (en) 2008-10-10
PT1355673E (pt) 2012-08-31
IS6881A (is) 2003-07-22
EP2332581B1 (fr) 2015-07-01
LU92108I9 (fr) 2019-01-15
JP2011140522A (ja) 2011-07-21
CA2435681C (fr) 2011-06-21
ZA200306176B (en) 2005-03-30
CA2435681A1 (fr) 2002-08-01
KR100947751B1 (ko) 2010-03-18
KR20030084913A (ko) 2003-11-01
MX341760B (es) 2016-09-02
NZ622900A (en) 2015-11-27
JP2016128526A (ja) 2016-07-14
US8741314B2 (en) 2014-06-03
LT5177B (lt) 2004-11-25
FR12C0072I1 (fr) 2013-01-04
HRP20030598A2 (en) 2005-06-30
BRPI0206672B8 (pt) 2021-05-25
LV13128B (en) 2004-07-20
CN1610560A (zh) 2005-04-27
LU92108I2 (fr) 2013-01-29
US10617766B2 (en) 2020-04-14
CY1113072T1 (el) 2015-08-05
AU2010219288A1 (en) 2010-09-23
TNSN03041A1 (en) 2005-12-23
WO2002058737A3 (fr) 2003-05-22
EA200300827A1 (ru) 2004-06-24
NO20033816L (no) 2003-09-11
LT2003071A (en) 2004-08-25
PT2332581E (pt) 2015-10-16
NZ602682A (en) 2014-05-30
US8734813B2 (en) 2014-05-27
CN100556459C (zh) 2009-11-04
ES2892316T3 (es) 2022-02-03
ES2544979T3 (es) 2015-09-07
EP2957300B1 (fr) 2021-07-14
AU2007216743A1 (en) 2007-10-04
EP2332581A1 (fr) 2011-06-15
US9173955B2 (en) 2015-11-03
CY2012030I2 (el) 2016-08-31
JP2014043475A (ja) 2014-03-13
US20150174259A1 (en) 2015-06-25
BRPI0206672B1 (pt) 2018-11-06
HUS1600040I1 (hu) 2019-05-28
US8722062B2 (en) 2014-05-13
RO122761B1 (ro) 2010-01-29
UA92579C2 (ru) 2010-11-25
DK1355673T3 (da) 2012-09-17
PL226184B1 (pl) 2017-06-30
US8999354B2 (en) 2015-04-07
WO2002058737A2 (fr) 2002-08-01
IL225522A (en) 2016-04-21
HUP0302999A2 (hu) 2003-12-29
IL225522A0 (en) 2013-06-27
NO20033816D0 (no) 2003-08-27
US20140308311A1 (en) 2014-10-16
CR7035A (es) 2008-11-25
EP2957300A3 (fr) 2016-03-30
FR15C0094I2 (fr) 2017-05-19
GEP20053691B (en) 2005-12-12
OA12590A (en) 2006-06-08
DK2332581T3 (en) 2015-10-05
HU230490B1 (hu) 2016-08-29
KR100947757B1 (ko) 2010-03-18
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
FR22C1001I1 (fr) 2022-02-18
US9844601B2 (en) 2017-12-19
MXPA03006561A (es) 2004-10-15
FR15C0094I1 (fr) 2016-01-22
KR20090029857A (ko) 2009-03-23
EA006947B1 (ru) 2006-06-30
HRP20030598B1 (hr) 2013-05-31
US10143757B2 (en) 2018-12-04
US20190060475A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
FR22C1001I2 (fr) Vaccin conjugué de protéine et de polysaccharide pour méningococcie polyvalente
DZ3399A1 (fr) Composition de vaccin polyvalent
CY2011001I1 (el) Εμβολια συνδυασμου για neisseria meningitidis
EP1572124A4 (fr) Compositions de vaccin vhc e1e2
AU2002354804A1 (en) Polyvalent conjugate vaccine for cancer
ATE553776T1 (de) Multivalente impfstoffzusammensetzung
HUP0103100A3 (en) Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
DZ3219A1 (fr) Vaccin
EP1423141A4 (fr) Vaccin
EP1322328A4 (fr) Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
PT2348036E (pt) Novas composições imunogénicas para a prevenção e tratamento da doença meningocócica
AU2003257003A8 (en) Chimeric multivalent polysaccharide conjugate vaccines
FR16C0014I2 (fr) Vaccin contre le virus de la fievre du nil
EP1337149A4 (fr) Immunotherapie vaccinale pour patients immunodeprimes
EP1565583A4 (fr) Formulations de vaccin anti-vih
ATE398109T1 (de) 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden
EP1389043A4 (fr) Vaccin contre le virus de la maladie de la fievre aphteuse
DE60222900D1 (de) Uv-abschirmende peptid-flavonoid konjugate
FR2741077B1 (fr) Vaccin polyvalent anti-dengue
EP1189632A4 (fr) Vaccin a combinaison de proteines de surface pneumococciques
NO20032957L (no) Farmasöytisk emulsjonspreparat
EP1594899A4 (fr) Vaccin idiotypique
PL346645A1 (en) IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
DE60107973D1 (de) Gewebehandlungszubereitung